In alignment with Q-linea's commercialisation strategy and to make ASTar commercially available to more customers in Europe, the company has signed a non-exclusive distribution agreement for Poland with Integra Diagnostic Sp. z.o.o.. The ambition is to continue partnering with strong distributors in other areas during the year.

“We have known Integra’s management team for many years, and they have always expressed an interest in distributing ASTar. There are larger public tenders coming up and we are excited to partner with Integra Diagnostic to leverage these. The partnership is also an important step to demonstrate that we are following our commercialisation strategy and that the interest to distribute ASTar is large. Our goal is that this will translate into sales during the year, but primarily it will have an impact on 2024 sales due to long sales cycles,” said Jonas Jarvius, CEO of Q-linea.

About ASTar Instruments and ASTar BC G-Kit 
ASTar Instrument and ASTar BC G-Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.
 
ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.